Advanced Age, Cardiovascular Risk Burden, and Timed Up and Go Test Performance in Parkinson Disease

被引:11
|
作者
Kotagal, Vikas [1 ]
Albin, Roger L. [1 ,2 ,3 ]
Mueller, Martijn L. T. M. [4 ]
Koeppe, Robert A. [4 ]
Studenski, Stephanie [5 ]
Frey, Kirk A. [1 ,4 ]
Bohnen, Nicolaas I. [1 ,2 ,3 ,4 ]
机构
[1] Univ Michigan, Dept Neurol, Ann Arbor, MI USA
[2] VAAAHS, Neurol Serv, Ann Arbor, MI USA
[3] VAAAHS, GRECC, Ann Arbor, MI USA
[4] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA
[5] Univ Pittsburgh, Div Geriatr, Dept Internal Med, Pittsburgh, PA 15260 USA
基金
美国国家卫生研究院;
关键词
Aging; Parkinson disease; Framingham risk score; Dopamine; Cardiovascular risk factors; VESICULAR MONOAMINE TRANSPORTER; POSITRON-EMISSION-TOMOGRAPHY; MILD COGNITIVE IMPAIRMENT; THERAPEUTIC IMPLICATIONS; PROSPECTIVE COHORT; OLDER-ADULTS; DEMENTIA; FRAILTY; INCIDENT; BINDING;
D O I
10.1093/gerona/glu070
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background. Cardiovascular comorbidities are a known risk factor for impaired mobility in elderly individuals. Motor impairments in Parkinson disease are conventionally ascribed to nigrostriatal dopaminergic denervation although progressive gait and balance impairments become more common with aging and often show limited response to dopaminergic replacement therapies. Methods. We explored the association between elevated cardiovascular risk factors and performance on the Timed Up and Go test in cross-sectional of Parkinson disease subjects (n = 83). Cardiovascular risk factor status was estimated using the Framingham General Cardiovascular Disease risk-scoring algorithm in order to dichotomize the cohort into those with and without elevated modifiable cardiovascular risk compared with normative scores for age and gender. All subjects underwent clinical and neuroimaging evaluations including a 3-m Timed Up and Go test, [C-11]dihydrotetrabena zine positron emission tomography imaging to estimate nigrostriatal dopamine terminal loss, and an magnetic resonance imaging assessment of leukoaraiosis. A similar analysis was performed in 49 healthy controls. Results. After adjusting for disease duration, leukoaraiosis, and nigrostriatal dopaminergic denervation, Parkinson disease subjects with elevated Framingham risk scores (n = 61) displayed slower Timed Up and Go test performance (beta= 1.86, t = 2.41, p = .018) compared with subjects with normal range Framingham risk scores (n = 22). When age >= 65 was added to the model in a post hoc analysis, the strength of effect seen with older age (beta = 1.51, t = 2.44, p = .017) was similar to that of elevated Framingham risk scoring (beta = 1.87, t = 2.51, p = .014). In a multivariable regression model studying the healthy control population, advanced age (t = 2.15, p = .037) was a significant predictor of Timed Up and Go speed though striatal [C-11]dihydrotetrabenazine (t = -1.30, p = .19) and elevated Framingham risk scores (t = 1.32, p = .19) were not. Conclusions. Modifiable cardiovascular risk factors and older age may independently exacerbate balance-related disability in Parkinson disease and may exert additive or synergistic pathological effects. The pathophysiology of these impairments cannot be explained completely by nigrostriatal dopaminergic denervation or leukoaraiosis burden and may relate to systemic factors seen with accelerated aging.
引用
收藏
页码:1569 / 1575
页数:7
相关论文
共 50 条
  • [1] Amyloid plaque burden and dual tasking impairments on the Timed up and go test in Parkinson disease
    Harrie, Ashley
    Hampstead, Benjamin
    Lewis, Catherine
    Herreshoff, Emily
    Kotagal, Vikas
    [J]. NEUROLOGY, 2023, 100 (17)
  • [2] Asymmetry In Parkinson's Disease Is Reflected In The Timed Up And Go Test
    Rose, Kyle M.
    Van Gemmert, Arend W. A.
    Hondzinski, Jan M.
    Li, Li
    [J]. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2012, 44 : 543 - 543
  • [3] uTUG: An unsupervised Timed Up and Go test for Parkinson's disease
    Tavares, Joao Elison da Rosa
    Ullrich, Martin
    Roth, Nils
    Kluge, Felix
    Eskofier, Bjoern M.
    Gassner, Heiko
    Klucken, Jochen
    Gladow, Till
    Marxreiter, Franz
    da Costa, Cristiano Andre
    Righi, Rodrigo da Rosa
    Barbosa, Jorge Luis Victoria
    [J]. BIOMEDICAL SIGNAL PROCESSING AND CONTROL, 2023, 81
  • [4] Is the timed ''up and go'' test an effective measure of functional performance in individuals with Parkinson's disease?
    Flynn, SM
    Behman, AL
    Thigpen, MT
    Light, KE
    [J]. JOURNAL OF AGING AND PHYSICAL ACTIVITY, 1997, 5 (04) : 368 - 368
  • [5] Dual Tasking With the Timed "Up & Go" Test Improves Detection of Risk of Falls in People With Parkinson Disease
    Vance, Roisin C.
    Healy, Dan G.
    Galvin, Rose
    French, Helen P.
    [J]. PHYSICAL THERAPY, 2015, 95 (01): : 95 - 102
  • [6] Validating a virtual Timed Up and Go (vTUG) test in Parkinson's Disease
    Matthews, C.
    Roberts, R.
    Davies, E.
    Falkenburger, B.
    Grobe-Einsler, M.
    [J]. MOVEMENT DISORDERS, 2022, 37 : S195 - S195
  • [7] Reliability of measurements obtained with the Timed "Up & Go" Test in people with Parkinson disease
    Morris, S
    Morris, ME
    Iansek, R
    [J]. PHYSICAL THERAPY, 2001, 81 (02): : 810 - 818
  • [8] Timed Up and Go Test and the Risk of Parkinson's Disease: A Nation-wide Retrospective Cohort Study
    Yoo, Jung Eun
    Jang, Wooyoung
    Shin, Dong Wook
    Jeong, Su-Min
    Jung, Hee-Won
    Youn, Jinyoung
    Han, Kyungdo
    Kim, Bongseong
    [J]. MOVEMENT DISORDERS, 2020, 35 (07) : 1263 - 1267
  • [9] Frailty in Patients with Parkinson's Disease: Associations with Disability and Timed Up and Go Test
    Ozer, F. Firat
    Akin, S.
    Gultekin, M.
    Erturk, G.
    Ekinci, A.
    [J]. MOVEMENT DISORDERS, 2018, 33 : S486 - S486
  • [10] Cognitive correlates of dual tasking costs on the timed up and go test in Parkinson disease
    Harrie, Ashley
    Hampstead, Benjamin M.
    Lewis, Cate
    Herreshoff, Emily
    Kotagal, Vikas
    [J]. CLINICAL PARKINSONISM & RELATED DISORDERS, 2022, 7